Skip to main content
Premium Trial:

Request an Annual Quote

Jonathan Seaton

Illumina has appointed Jonathan Seaton as senior VP for corporate and business development. In this role, Seaton will be responsible for global business development activities, including strategic commercial deals, mergers and acquisitions, licensing, and partnerships. He joins Illumina from Becton Dickinson, where he was VP and head of strategy and business development for the Life Sciences segment. He previously held leadership roles at Hoffman-La Roche, Roche Tissue Diagnostics, LS9, and several consulting firms and investment banks.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.